HVTN starts trials to assess immune response to SARS-CoV-2 infection

HVTN starts trials to assess immune response to SARS-CoV-2 infection

The NIH-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) have initiated their first clinical trial to describe immune responses in study participants with a history of infection with SARS-CoV-2, the virus that causes COVID-19. The study, called HVTN 405/HPTN 1901, is underway at clinical trial sites across North and South
America.

“The study includes an important milestone needed for SARS-CoV-2 vaccine development and will help create the infrastructure required to do sophisticated vaccine trials,” said Dr Larry Corey MD, Protocol Chair and Principal Investigator, HVTN Leadership Operations Center which is based at the Fred Hutchinson Cancer Research Center.

HVTN 405/HPTN 1901 aims to enroll approximately 400 study participants aged 18 and older who tested positive for SARS-CoV-2 and have since recovered. Participants will have one required clinic visit and will have the option to participate in additional clinic visits two, four and twelve months
after the initial visit, according to an official statement. Each visit includes a blood draw and optional nasal sampling procedures. Individuals who still have symptoms of infection or asymptomatic individuals less than two weeks from the date of their last positive test will not be enrolled.

SARS-CoV-2 is the most infectious of three coronaviruses that have caused recent epidemics resulting in significant morbidity and mortality in humans in the past 20 years. Given the extent to which the disease has spread, mathematical modeling suggests that SARS-CoV-2 is likely to become endemic in human populations.